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The functional properties of actin-regulating formin proteins are diverse and in many cases cell-type speciﬁc.
FHOD1, a formin expressed predominantly in cells of mesenchymal lineage, bundles actin ﬁlaments and
participates in maintenance of cell shape, migration and cellular protrusions. FHOD1 participates in cancer-
associated epithelial to mesenchymal transition (EMT) in oral squamous cell carcinoma and breast cancer. The
role of FHOD1 in melanomas has not been characterized. Here, we show that FHOD1 expression is typically
strong in cutaneous melanomas and cultured melanoma cells while the expression is low or absent in benign
nevi. By using shRNA to knockdown FHOD1 in melanoma cells, we discovered that FHOD1 depleted cells are
larger, rounder and have smaller focal adhesions and inferior migratory capacity as compared to control cells.
Importantly, we found FHOD1 depleted cells to have reduced colony-forming capacity and attenuated tumor
growth in vivo, a ﬁnding best explained by the reduced proliferation rate caused by cell cycle arrest.
Unexpectedly, FHOD1 depletion did not prevent invasive growth at the tumor margins. These results suggest
that FHOD1 participates in key cellular processes that are dysregulated in malignancy, but may not be essential
for melanoma cell invasion.
1. Introduction
Cells undergo substantial functional alterations in order to obtain
proliferative, invasive and metastatic properties which are associated
with malignancy. Alterations that involve cell shape, signalling, adhe-
sion, and migration depend on eﬃcient remodelling of the actin
cytoskeleton. Actin ﬁlaments not only determine shape but also form
a scaﬀold for motor proteins that provide the contractile force for
invasive movement and serve as regulators of intracellular signalling
cascades. Dynamic actin ﬁlament remodelling is controlled by a
multitude of actin-associated molecules [1]. Several classes of actin
nucleating proteins assist the assembly of actin monomers into
ﬁlamentous structures. Among them, the formin family is the largest.
Formins are large multi-domain proteins, which are deﬁned by the
presence of a highly conserved formin homology 2 (FH2) domain. This
domain mediates nucleation or elongation of actin ﬁlaments. Other
domains, present in most formins, regulate activation/inactivation and
subcellular ﬁlament targeting. The biochemical properties of the
individual formins are distinct and sometimes even counteract each
other: once activated, they may nucleate, elongate, bundle, cap and
even severe actin ﬁlaments. On the cellular level, individual formins
have been shown to participate in the formation of diverse cellular
protrusions, adhesions, and inﬂuence serum response factor-mediated
transcription [2–4].
FHOD1 (formin homology 2 domain containing protein 1) is an
eﬃcient capping and bundling protein of actin ﬁlaments. In contrast to
the majority of formin proteins, it does not elongate actin ﬁlaments in
vivo [5]. The participation of FHOD1 in cytoskeletal remodelling and
cell migration has been established in ﬁbroblasts, melanoma cells and
breast cancer cells [6,7]. FHOD1 is one of formins regulating tran-
scription from the serum response element (SRE) [7,8]. This occurs
through changes in the pool of monomeric actin. With increased actin
ﬁlament polymerization, the pool of monomomeric actin is reduced,
which allows the release of megakaryoblastic leukemia 1 (MKL-1, a.k.a.
MAL or myocardin related transcription factor A, MRTF-A) which
translocates/accumulates in nuclei [9]. MKL-1 binds to the SRE,
http://dx.doi.org/10.1016/j.yexcr.2016.12.004
Received 27 April 2016; Received in revised form 30 November 2016; Accepted 1 December 2016
⁎ Correspondence to: Department of Pathology, Turku University Hospital, Kiinamyllynkatu 10, 20520 Turku, Finland.
1 These authors contributed equally to this work.
E-mail addresses: minna.peippo@utu.ﬁ (M. Peippo), maria.gardberg@utu.ﬁ (M. Gardberg), tarja.lamminen@utu.ﬁ (T. Lamminen), katja.kaipio@utu.ﬁ (K. Kaipio),
olli.carpen@utu.ﬁ (O. Carpén), vanina.heuser@utu.ﬁ (V.D. Heuser).
Experimental Cell Research 350 (2017) 267–278
Available online 02 December 2016
0014-4827/ © 2016 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
MARK
inducing transcription from many cytoskeletal and cell cycle progres-
sion associated genes [10,11]. FHOD1 has further been found to be
essential for nuclear movement and centrosome orientation in ﬁbro-
blasts polarizing for migration [12,13].
There are very few studies on formin expression and signiﬁcance in
clinical cancer. FMNL1 (Formin-like protein 1) is over-expressed in
non-Hodgkin lymphoma [14], and high FMNL2 (Formin-like protein
2) expression is associated with metastasis in colorectal cancer [15].
Recently, we found that high expression of FMNL2 in localized
cutaneous melanoma is associated with increased risk of recurrence
during follow-up. In cell lines, FMNL2 expression was dependent on
ERK MAPK signalling, a pathway commonly over activated melanoma
[16]. In another study, we found that FHOD1 expression increased
with cancer-associated EMT, a process that mediates invasion [17].
Intriguingly, FHOD1 has been shown to directly interact with compo-
nents of the ERK MAPK pathway [18], which suggests that FHOD1
could, if expressed in melanoma, be a link between altered signalling
and cellular behaviour. With this background, we wanted to investigate
FHOD1 expression in melanocytic neoplasms and explore its roles in
melanoma cell lines.
In this study, we found that FHOD1 is expressed in most
melanomas. In order to study the functional role of FHOD1 in
melanoma, we stably silenced FHOD1 expression in the WM164
melanoma cell line using shRNA constructs. Studying the eﬀects of
FHOD1 depletion, we found changes in cell morphology, migration,
colony formation, cell-spreading assays and cell cycle analysis in vitro.
Importantly, we found that tumor growth is reduced after FHOD1
depletion in a mouse melanoma xenograft model. Taken together, all
these results suggest a role for FHOD1 in melanoma tumorigenesis.
2. Material and methods
2.1. Tumor histology and immunohistochemistry
The mouse melanoma xenografts were paraﬃne embedded, sec-
tioned and hematoxylin and eosin stained. For immunohistochemistry,
slides were sectioned at 3 µm, stained for Ki-67 and cleaved caspase 3
using a Ventana Discovery XT autostainer device (Ventana Medical
Systems, Tucson, AZ). After a standard pretreatment with Cell
Conditioning Solution CC1 (Ventana), the slides were incubated with
a Ki-67 polyclonal antibody (1:1000, Chemicon International, Billerica,
MA) for 36 mins or Cleaved Caspase 3((D3E9) 1:100, Cell Signalling
Technology, Danvers, MA) for 40 min, respectively. OminMap anti-Rb
HRP using ChromoMap DAB, both from Ventana, were used for
detection. FHOD1 immunohistochemistry was performed using a
Labvision Autostainer device with a BrightVision Poly-HRP-anti-
Rabbit IgG detection kit according to the manufacturer's protocol
(Immunologic, Duiven, the Netherlands). The slides were pressure
cooked for 2 min for antigen retrieval. The primary antibody against
FHOD1 (1:150, Sigma-Aldrich, St Louis, MI) was incubated for 1 h, the
secondary antibody for 30 min. This antibody has been extensively
characterized previously [17]. Diaminobenzene was used as chromo-
gene.
The tumor histology was evaluated by microscopy of HE-stainings.
For analysis of cell diameter and of Ki-67 staining, four photomicro-
graphs were taken at 400x magniﬁcation from diﬀerent tumors in each
treatment group. The diameter of at least 50 cells was measured from
each micrograph.
For the study of FHOD1 expression in nevi and melanoma, 8
benign nevi and 10 melanoma +3 paired metastatic melanoma FFPE
samples were sectioned and immunohistochemically stained as de-
scribed above for mouse xenografts. The samples were collected from
the tissue archive of the Department of Pathology at Turku University
Hospital with the approval of the Joint Committee on Ethics of the
University of Turku and Turku University Hospital.
2.2. Cell lines and culture conditions
Metastatic melanoma cell lines WM164 and WM239 (BRAF V600E
and BRAF V600D, respectively) were cultured in RPMI 1640 medium
(Gibco-BRL, Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) (Biowest), 5 mM Ultraglutamine I (Lonza, Basel,
Switzerland), 1 x non-essential amino acids (NEAA) (Lonza), and
100 U/ml penicillin-streptomycin (Gibco). Cutaneous Bowes melano-
ma cell line (BRAF WT) and the metastatic SK-Mel-28 cells (BRAF
V600E mutated) were cultured in EMEM (Gibco) and MEM (Gibco),
respectively, supplemented with 10% FBS, 5 mM Ultraglutamine I, and
100 U/ml penicillin-streptomycin. Malme-3 M (BRAF V600E mutated)
metastatic cells were maintained in DMEM (Lonza) containing all the
mentioned supplements.
2.3. Western blotting
Cells were harvested and lysed in RIPA buﬀer (50 mM Tris-HCl,
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
supplemented with inhibitors (1xComplete Mini -protease inhibitor
cocktail [Roche] and 1XPhosStop a phosphatase inhibitor cocktail
[Roche]). Insoluble cell debris was removed by centrifugation
(21,000g for 30 min at 4 °C). The protein concentration of lysates
was determined by the Bradford method (BioRad) before adding 5x
Laemmli to samples. Equal amounts of total protein were separated by
SDS-PAGE and transferred to nitrocellulose membrane (Whatman
PROTRAN, PerkinElmer). The membranes were blocked with 5% dry
milk in TBST (TBS, 0.1% Tween) and immunoblotted with diﬀerent
antibodies diluted in 5% bovine serum albumin (BSA) in TBST.
The rabbit anti-human FHOD1 antibody (Sigma-Aldrich) was used
at 1:1000. The mouse anti-α-tubulin antibody (Sigma-Aldrich) was
used 1:10,000 as a control for protein loading. The secondary
antibodies were HRP-conjugated swine anti-rabbit and HRP-conju-
gated rabbit anti-mouse immunoglobulins (1:2500, Dako) diluted in
block solution. Membranes were washed three times with TBST
between the diﬀerent steps.
2.4. Generation of stable FHOD1 knockdown cell lines
For establishment of stable FHOD1 knockdown cell lines, 300×103
WM164 cells were transfected in a 24 well plate using 2 μl of
Lipofectamine 2000 (Life Technologies, Carlsbad, CA, USA) and
50 ng of pRFP-C-RS HuSH shRNA RFP vectors (Origene, Rockville,
MD, USA) containing either the scrambled shRNA cassette TR30015
(scramble control), human FHOD1 targeting shRNAs FI351919
(CGCTGTGCCAAGGTGGACTTTGAACAGCT; shRNA 1) or FI351920
(CCGAGACAGAGAAGTTCTCAGGTGTGGCT; shRNA 2). The transfec-
tion medium was changed after 24 h and the cells were kept in
selection medium containing 1.0 µg/ml puromycin (Sigma) for 2
weeks. Next, the cells were transferred to 10 cm dish and colonies
expressing RFP (red ﬂuorescence protein) were isolated, ampliﬁed and
analysed for FHOD1 expression by western blotting.
The FHOD1 shRNA clones were stable in culture and maintained a
low FHOD1 level for at least 15 passages in medium which contained
0.5 µg/ml puromycin. Similar passages of the 3 clones were used in all
the following studies.
2.5. Cell Immunoﬂuorescence stainings and microscopy
Cells were plated on gelatin (Sigma-Aldrich) precoated coverslips
(13 mm) and grown in complete medium for 24 h. Next, the cells were
ﬁxed with 4% paraformaldehyde for 10 min at room temperature. The
coverslips were washed with PBS and blocked with 3% BSA, 5% dry
milk, 0.5% triton X-100 in PBS for 45 min. The rabbit anti-FHOD1
(1:200, Millipore) antibody was incubated 1 h at room temperature.
Next, the coverslips were incubated with Alexa Fluor 568 goat anti-
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rabbit IgG (1:500, Invitrogen) or Alexa Fluor 488 goat anti-mouse IgG
(1:500, Invitrogen).
Alexa Fluor 488 or 546-conjugated phalloidin (1:100, Invitrogen)
were incubated together with the secondary antibodies in order to
visualize ﬁlamentous actin. The mounting media contained DAPI for
staining nuclei (ProLong® Gold Antifade Mountant with DAPI, Life
Technologies). After each staining step, the cells were washed three
times with PBS. Images were taken with an Olympus BX60 ﬂuores-
cence microscope. The images (1360×1024 px) were analysed with
ImageJ 1.49b software (http://rsbweb.nih.gov/ij/) for quantiﬁcation of
changes in morphology. Cell circularity was measured using ImageJ
(Measure and Analyze Particles commands; circularity=4pi(area/
perimeter^2). A circularity value of 1.0 indicates a perfect circle. For
actin ﬁlament quantiﬁcation, mean intensity of ﬂuorescent phalloidin
in cell cytoplasm was calculated for 100 cells per cell line in 8 bit
pictures using "IntDen" (Integrated Density; the product of Area and
Mean Gray Value).
2.6. Migration and invasion assay
50×103 cells were grown overnight in 96-well Essen BioScience
ImageLock microplates coated with 100 μg/ml of Matrigel (Corning,
Lowell, MA) in complete medium. Wounds were precisely made by the
96-pin Wound-Maker provided with the IncuCyte FLR (Essen
Bioscience, Ann Arbor, MI). After washing thoroughly with PBS to
remove the detached cells, wounds were covered with 50 μl of Matrigel
(for invasion) or 50 μl of medium (for migration). After 30 min in the
incubator, 100 μl of completed medium was added and the cells were
placed in the IncuCyte FLR. The wound images were automatically
acquired by IncuCyte FLR from the incubator at 2 h intervals for 48 h.
The kinetics of the relative wound density was analysed by IncuCyte™
software.
2.7. Transwell cell migration analysis
50×103 cells in 150 μl of medium without FBS were loaded in
Boyden chambers (Millipore) placed in 24 well plates containing 900 μl
of complete medium with 10% FBS. Cells were allowed to migrate
through porous (8 µm) membranes for 48 h. After medium removal the
chambers and wells were washed once with PBS. Non-migrating cells
were removed from the upper chamber with a cotton swab, whereas
migrating cells adherent to the underside of the ﬁlter were ﬁxed and
stained with Crystal Violet solution (0.05% Crystal Violet, 1%
Formaldehyde, 1% methanol, PBS) for 10 min. The inserts were
washed with water and allowed to dry overnight. The migrated cells
were photographed in 4 random sites by light microscopy at a
magniﬁcation of 100X. To quantify the amount of migrated cells in
another way, 1% SDS (400 μl per membrane in 24 well plate) was
added to solubilize the stain from cells. Plate was agitated on an orbital
shaker for 30 min until the colour of the membranes was uniform. The
absorbance of each sample was measured at 570 nm with Multiskan FC
Machine (Thermo Scientiﬁc).
2.8. Cell-spreading assay
For the cell-spreading assay 25×103 cells were seeded in 96 well
plate (4 wells/cell line/experiment) precoated with ﬁbronectin (25 μg/
ml, Sigma-Aldrich). Cells were allowed to attach for 60 min, then ﬁxed
and stained with Crystal Violet for 10 min at room temperature and
washed 5 times with distilled water. Representative pictures were taken
from each well using 100X objective of a light microscope (Olympus
IX70). Images (1280×1024 pixels) were analysed using ImageJ 1.49b.
The experiment was repeated four times.
2.9. Focal adhesion analysis
Cells were grown on coverslips previously precoated with ﬁbronec-
tin (25 μg/ml). The cells were allowed to attach for 60 min, then ﬁxed
and stained as previously described. Focal adhesions were visualized
with Anti-Paxillin antibody (1:100, Transduction Laboratories) and
images were taken using 10X objective with an Olympus BX60
ﬂuorescence microscope. The images (2040×1536 px) were analysed
with ImageJ 1.49b software for quantiﬁcation of changes on size and
number of focal adhesions. The average area and number of focal
adhesions per cell were quantiﬁed from binary images using the
Analyze Particle tool in ImageJ. Particles larger than 0.2 µm2 were
counted as focal adhesions.
2.10. Colony formation assay
2×103 cells were mixed in 500 μl complete medium containing
0.3% agarose and plated in 12 well plates (4 wells/cell line/experiment)
previously precoated with 500 μl of 0.5% agar in the same medium.
Cells were allowed to grow for 2 weeks. Eight random pictures
(1280×1024 pixels) were taken from each well using 4X objective of
a light microscope (Olympus IX70). The percentage of colonies (more
than 30 cells) with diameter greater than 100 µm was calculated using
ImageJ 1.49b software.
2.11. Proliferation assay
5×103 cells were plated in 96 well plates and allowed to grow for
72 h. Phase-contrast images were automatically acquired by IncuCyte
FLR (Essen Bioscience) from the incubator at 2 h intervals.
Proliferation was monitored by analyzing the occupied area (% con-
ﬂuence) of cell images over time by IncuCyte™ software (Essen
Bioscience). The experiment was repeated four times.
2.12. Flow cytometric analysis
For cell cycle analysis 15×105 cells in 6 well plates were kept with
serum free medium for 48 h and then trypsinised and resupended in
PBS. Analysis of cell viability was performed using Propidium Iodide
(Molecular Probes, Eugene OR, USA) according to manufacturer's
instructions followed by ﬂuorescence activated cell sorting with FACS
Fortessa, (BD Biosciences, NJ, USA). Data obtained from the cell cycle
distributions were analysed with FlowJo ﬂow cytometry analysis soft-
ware (Ashland, OR, USA).
2.13. Mouse model/inoculations
All animal experiments and handling were performed in accordance
with the Finnish Animal Experiment Board and the institutional
animal care policies of Turku University, Central Animal Laboratory,
which fully meet the requirements as deﬁned in the U.S. National
Institutes of Health guidelines on animal experimentation. Adult
female athymic nude Foxn1nu mice (Harlan laboratories, The
Netherlands) were housed with free access to irradiated food (SDS
RM3 (E) Soya free, irr. 25 kGy, Special Diet Service) and sterilized
water under controlled conditions of light (12 h light/dark cycle) and
temperature.
Three mice per cell line were subcutaneously inoculated in both
ﬂanks with 1×106 cells in 75 μl of RPMI media mixed with 75 μl of
Matrigel (BD Biosciences). Mice were weighed weekly and tumor
growth was measured with calipers to get the volume ([πlength x
width2]/6) and by optical imaging (IVIS Spectrum, Perkin Elmer). The
RFP ﬂuorescence images were acquired using 570 nm excitation and
620 nm emission ﬁlters. When the tumor size at least in one mouse/
group reached the level of predetermined maximal tumor size (17 mm
length as determined in the animal experiment license), all mice in the
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study group were euthanized under isoﬂurane anesthesia by blood
collection through heart puncture and neck dislocation. Tumors and
organs which showed ﬂuorescence in IVIS imaging were ﬁxed in 10%
formalin for 24 h and paraﬃne-embedded (FFPE) for histological and
immunohistochemical analysis.
2.14. MKL-1 nuclear translocation
WM164 cells lines were plated on gelatin coated coverslips and kept
on incubator overnight with complete medium. Medium was replaced
by starvation medium for 72 h before 20 min stimulation with medium
containing 10% serum. Cell were washed with PBS and ﬁxed using 4%
PFA for 10 min in room temperature. MKL-1 staining was done as
described above using a goat polyclonal anti MKL1 (MRTF-A) antibody
(Santa Cruz) fallowed by Alexa Fluor 488 Donkey anti-Goat IgG
secondary antibody together with Alexa Fluor 546-conjugated phalloi-
din (1:100, Invitrogen) in order to visualize ﬁlamentous actin. The
mounting media contained DAPI for staining nuclei (ProLong® Gold
Antifade Mountant with DAPI, Life Technologies). After each staining
step, the cells were washed three times with PBS. Images were taken
with an Olympus BX60 ﬂuorescence microscope. The images
(2040×1536 px) were analysed with ImageJ 1.49b software (http://
rsbweb.nih.gov/ij/) for quantiﬁcation of MKL-1 positive nuclei of 1500
cells/cell line.
2.15. Statistical analysis
All the experiments were repeated three times, unless indicated.
One-way ANOVA was performed using Tukey's multiple comparison
procedure to identify the diﬀerences between cell lines and error bars
represent SEM.
3. Results
3.1. FHOD1 expression in melanocytic tumors and melanoma cell
lines
First, we wanted to establish whether FHOD1 is expressed in
human melanocytic tumors. For this purpose, 8 benign melanocytic
nevi and 10 primary melanomas were immunohistochemically stained
with a FHOD1 antibody. FHOD1 expression was found to be very low
or absent in all benign nevi (Fig. 1A, upper panel). Clear upregulation
could be seen in most primary melanoma and metastatic melanoma
samples, as moderate or strong FHOD1 staining was seen in 8/10 cases
(Fig. 1A, lower panel). The staining was similar in tumor centres and at
tumor margins. In 2/10 melanoma samples, FHOD1 immunoreactivity
was weak, comparable to the staining intensity seen in benign nevi.
Next we studied the expression of FHOD1 in several melanoma cell
lines by western blotting. All studied cell lines expressed FHOD1, but
the expression level varied. We found moderate FHOD1 expression in
the Bowes cell line, high expression in SK-MEL-28, WM164 and
WM239, while there was low expression Malme-3M (Fig. 1B).
Immunoﬂuorescence double staining with anti-FHOD1 and phalloidin
showed FHOD1 to be localized in the cytoplasm of WM164 cells,
mostly as small dots, but also along actin ﬁlaments (Fig. 1C).
We have earlier shown that FHOD1 expression is dependent of
PI3K signalling, but not MAPK signalling in oral SCC cells [17] In line
with the result in SCC cells, melanoma cell lines with active PI3K
signalling lost FHOD1 expression with PI3K inhibition, while MAPK
inhibition had neglible eﬀect (not shown).
3.2. Phenotypic alterations in WM164 melanoma cells after FHOD1
knockdown
To investigate the functions of FHOD1 in the WM164 melanoma
cell line, cells were transfected with shRNA plasmids either speciﬁcally
targeting human FHOD1 mRNA or a scrambled control shRNA.
Several stable clones with reduced FHOD1 were obtained and further
analysed. Clones in which levels of FHOD1 protein were reduced 80%
and 95% compared with parental or scrambled control cells were
chosen for further experiments. These clones were named FHOD1 20%
and FHOD1 < 5%, respectively. Scrambled control cells were named
FHOD1 100% (Fig. 2A).
The reduction of FHOD1 was accompanied by a change in cellular
morphology. The FHOD1 silenced melanoma cells contained less actin
ﬁlaments, as demonstrated by ﬂuorescent phalloidin staining (Fig. 2C,
upper panel). Fluorescent actin ﬁlaments were quantiﬁed with ImageJ,
by measuring mean intensity of ﬂuorescence in cells. FHOD1 20% and
FHOD1 < 5% had 25% and 10% less actin ﬁlaments compared to
FHOD1 100% (not shown). The FHOD1 < 5% cells were less polarized,
resulting in larger cells with a rounder shape. When quantiﬁed from
the cell outline pictures (Fig. 2C, lower panel), the total area and
circularity was signiﬁcantly increased in FHOD1 < 5% (n=90) com-
pared to both FHOD1 20% (n=91) and FHOD1 100% (n=101)
(Fig. 2B).
3.3. Eﬀects of FHOD1 silencing on melanoma cell migration,
spreading and adhesion
To test whether the cells were able to migrate after FHOD1
knockdown, a wound healing migration assay was performed
(Fig. 3A). The knockdown cells FHOD1 20% and FHOD1 < 5% showed
signiﬁcant healing delay in comparison to the control FHOD1 100%
(P≤0.001 and P≤0.01 respectively, ANOVA). Next, the cells were
challenged to invade into a Matrigel plug in the wound healing assay.
Also invasion was reduced after FHOD1 depletion (Fig. 3B). The
diﬀerence was highly signiﬁcant in both FHOD1 depleted groups
(P≤0.001). Transwell migration, using Boyden chambers and serum
gradient, was used to challenge the cells to migrate as single cells
(Fig. 3C and D). Knockdown cells lines FHOD1 20% and FHOD1< 5%
migrated signiﬁcantly less than the control FHOD1 100% cell line
(P≤0.01, ANOVA).
Cancer-associated EMT could account for increased migration and
invasion. To check whether FHOD1 knockdown induces EMT, the
expression of well-established EMT-markers vimentin, slug, snail, E-
cadherin, N-cadherin, β Catenin, were investigated. No changes were
found in western blotting, indicating that mesenchymal transcription
factors were equally expressed in the knockdown and control cells (data
not shown).
Cell spreading initiates adhesion in vitro. We asked whether the
inferior migratory capacity of FHOD1 depleted cells might be related to
adhesive properties. To test this, a cell-spreading assay was performed.
FHOD1 depleted and control cells were seeded on ﬁbronectin-coated
wells, ﬁxed and stained after 60 min (Fig. 4A). The percentage of cells
with spread morphology and cell areas were calculated (Fig. 4B and C).
We found that a higher percentage of cells were spread in the FHOD1
depleted groups. The spread cells further had a greater cell area than
the control cells. The diﬀerence was statistically signiﬁcant in the
FHOD1 < 5% cell line. The increased spreading of FHOD1 depleted
cells suggested that adhesive structures might be altered. To visualize
and evaluate focal adhesions, cells were stained for the focal adhesion
protein paxillin (Fig. 4D). FHOD1 silenced cells contained signiﬁcantly
smaller focal adhesions (Fig. 4F), but yet the number of focal adhesions
did not diﬀer from control cells (Fig. 4E).
3.4. FHOD1 silencing reduces colony formation and proliferation
A colony-forming assay was performed by seeding cells in soft agar
and quantifying colonies with a diameter greater than 100 µm after 2
weeks (Fig. 5A). The percentage of colonies with diameter greater than
100 µm was signiﬁcantly higher in both FHOD1 100% and FHOD1
20% as compared to FHOD1 < 5%, while the number of FHOD1 20%
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colonies did not signiﬁcantly diﬀer from the control (Fig. 5B).
Using IncuCyte™ live cell imaging, proliferation was monitored by
analyzing the area occupied by cells (% conﬂuence). The conﬂuence of
cells growing in normal conditions for 72 h showed that FHOD1
knockdown signiﬁcantly reduces proliferation in WM164 melanoma
cells (Fig. 5C).
To investigate the reduced proliferation further, cleaved caspase 3
expression was studied by western blotting. No increase of cleaved
caspase was detected after FHOD1 knockdown (data not shown),
suggesting that increased apoptosis does not account for reduced
proliferation and colony formation. Cell cycle analysis, however,
revealed a mechanistic explanation for the reduced proliferation. In
FACS analysis, a signiﬁcant arrest of FHOD1 depleted cells in G0+G1
was found (Fig. 5D).
3.5. FHOD1 knockdown reduces tumor growth in vivo
To study whether the eﬀects of FHOD1 knockdown were relevant
for tumor formation in vivo, FHOD1 depleted or control cells were
injected subcutaneously in both ﬂanks of athymic nude mice. Tumor
growth was measured with calipers and optical imaging using IVIS
Spectrum. Images of mice from diﬀerent treatment groups at day 14
are presented in Fig. 6A. The cell lines regrettably had diﬀerent levels
of red ﬂuorescence, making intergroup comparison by this method
inappropriate. Therefore measurements with calipers were chosen as
follow-up method. By palpation, the tumors grew at diﬀerent rates
between the groups; therefore mouse groups were sacriﬁced at diverse
time points. Tumors derived from the FHOD1 100% cell line grew
faster than FHOD1 depleted groups, resulting in sacriﬁce due to large
Fig. 1. FHOD1 expression levels in melanocytic neoplasms and in melanoma cell lines. A) FHOD1 expression is low or absent in benign nevi (upper panel). In melanomas,
FHOD1 expression is usually strong to moderate (lower panel, left and middle), but occasional low expression can be found (lower panel, right). Scale bars: 100 µm. B) FHOD1
expression levels in melanoma cell lines Bowes, SK-MEL-28, WM239, WM164 and Malme-3 M. WM164 was chosen for stable FHOD1 knockdown. α-tubulin was used as a control for
protein loading. C) FHOD1 is localized in the cytoplasm and along the actin ﬁlaments stained with Alexa Fluor 488-conjugated phalloidin. Scale bars: 20 µm.
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tumor size at day 14 (Fig. 6B). At this time point a statistical diﬀerence
in the tumor size was observed for the FHOD1 20% compared to
control FHOD1 100% (P≤0.01, ANOVA) (Fig. 6C). We could see
statistical diﬀerence (P≤0.01) also when FHOD1 20% and FHOD1 <
5% results were combined and then compared with the control using t-
test (results not shown). In the FHOD1 depleted groups, the size limit
was reached at 30 days for FHOD1 20%, and at 22 days for and
FHOD1 < 5% (Fig. 6B). No ﬂuorescence was detected in any of the
collected organs thus no further analysis were done.
Histologically, mouse tumors formed by WM164 melanoma cells
expressing diﬀerent levels of FHOD1 were slightly diﬀerent (Fig. 6D,
top row). FHOD1 100% cells grew diﬀusely, whereas FHOD1 20% and
FHOD1 5% formed a slightly lobular architecture, with strands of
connective tissue seen within the tumor. In all three groups, the edges
of the tumors were morphologically invasive. The size of the tumor cells
was quantiﬁed, and found to be unaltered (results not shown).
FHOD1 immunohistochemistry revealed strong and diﬀusely cyto-
plasmic expression in FHOD1 100% tumors. In the knockdown
tumors, a minor diﬀuse expression was seen in FHOD1 20% cells,
and small islands of clearly FHOD1 positive cells were scattered in both
FHOD1 20% and more frequently in FHOD1 5% groups (Fig. 6D,
middle row). The clearer reduction of tumor growth in FHOD1 20%
compared to FHOD1 < 5% may be explained by the groups of FHOD1
expressing cells within the FHOD1 < 5% tumors (Fig. 6D). The reduc-
Fig. 2. FHOD1 silenced WM164 melanoma cells are larger and more circular than control cells. A) FHOD1 expression in shRNA-expressing clones transfected with
plasmids containing two shRNA sequences targeting human FHOD1 or a scrambled control sequence: FHOD1 100% (scramble control, transfected with shRNA TR30015), FHOD1 20%
(transfected with shRNA FI351920), and FHOD1 < 5% (transfected with shRNA FI351919). Tubulin expression was used as a loading control. B) Morphological analysis of the cell lines
expressing diﬀerent levels of FHOD1. C) Representative images of FHOD1 stable knockdown cells stained with Alexa Fluor 488-conjugated phalloidin (upper panel) and the cell outline
pictures (lower panel). Actin ﬁlaments in cells were quantiﬁed with ImageJ, by measuring mean intensity of ﬂuorescence in cells. FHOD1 20% and FHOD1 < 5% had 25% and 10% less
actin ﬁlaments compared to control (not shown). ** P≤0.01, ANOVA, Tukey. Scale bars: 50 µm.
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tion of FHOD1 expression in the majority of cells corresponded to the
levels previously estimated by western blotting (Fig. 2A). The tumors
were stained for cleaved caspase 3, but no change was seen between
groups, indicating that the eﬀect of FHOD1 depletion on tumor growth
is not due to increased apoptosis (results not shown). In Ki-67 staining,
however, a clear reduction of proliferation was seen (Fig. 6D, bottom
row; Fig. 6E) as a result of FHOD1 depletion. The reduced rate of
proliferation most probably account for the slower growth of FHOD1
depleted tumors, reﬂecting the cell cycle arrest found in vitro.
Cell cycle arrest could possibly relate to the SRE, since it controls
the expression genes involved in cell cycle progression. We wondered if
FHOD1 knockdown could reduce the serum response that leads to
transcription from the SRE. To address this issue, we measured the
nuclear translocation of the SRE co-activator MKL-1 from the cyto-
plasm in FHOD1 control and knockdown cells after serum stimulation.
The number of MKL-1 positive nuclei was signiﬁcantly lower in
FHOD1 depleted cells, suggesting that FHOD1 is aﬀecting transcrip-
tion from the SRE (Fig. 7A and B).
4. Discussion
While the understanding of melanoma biology and therapeutic
alternatives are expanding rapidly, the mechanisms regulating mela-
noma cell growth and invasion are incompletely understood. Here we
studied the association of FHOD1, a formin only recently associated
with cancerous phenotypes, in melanoma using both tumor material
and experimental approaches. We provide several types of evidence
indicating an important role for FHOD1 in melanoma biology: First, we
show that FHOD1 expression is increased in human melanomas, as
compared to benign nevi. The expression in both nevi and melanomas
is diﬀerent from normal skin, where FHOD1 expression cannot be
detected [17]. Second, we detect roles for FHOD1 in adhesion and
migration as well as proliferation, all key processes that are dysregu-
lated malignant cells. Finally, we ﬁnd that FHOD1 participates in
tumor growth in vivo. This is the ﬁrst time FHOD1 expression has been
studied in clinical benign and malignant melanocytic neoplasms, and
the most comprehensive analysis of FHOD1 in melanoma biology to
Fig. 3. FHOD1 expression inﬂuences cell migration and invasion. In wound healing migration (A) and invasion (B) assays, FHOD1 depleted groups migrated and invaded
inferiorly as compared to the control group. C) Cell migration was further studied by a Boyden chamber assay. The images show the cells attached under the membranes, stained with
crystal violet. D) Quantiﬁcation of Boyden chamber migration results. Knockdown cells lines FHOD1 20% and FHOD1 < 5% crossed the membrane signiﬁcantly less eﬀectively than the
control FHOD1 100% cell line. ** P≤0.01, *** P≤0.001; ANOVA, Tukey.
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date.
The biochemical and cellular properties of individual formin
proteins have been intensively studied. Many cell-speciﬁc functions
have been described in detail. The expression and signiﬁcance of
formins in clinical cancer has not been as well characterized. In one
study, expression of a formin closely related to FHOD1, FMNL2, was
found to be increased in colorectal cancer and correlate with metastasis
[19]. FMNL2 expression has also been found in melanoma (discussed
further below). Another formin, FMNL1, is commonly overexpressed in
basal breast cancer, a breast cancer type with poor prognosis [20,21].
Furthermore, FHOD1 expression has been shown to increase in
malignancy: high expression is found in squamous cell carcinoma
(SCC), while expression is not detected in normal oral squamous
epithelium. In SCC cells, this upregulation is associated with EMT
[20,21]. Finding FHOD1 in cancers of epithelial lineage is intriguing,
since in normal tissues it is found mainly in cell types of mesenchymal
lineage, such as endothelial cells and smooth muscle cells. The ﬁndings
we describe here indicate that FHOD1 can be upregulated in malig-
nancy of neuroectodermal lineage as well. Further studies will be
needed to show whether FHOD1 upregulation is a common phenom-
enon in cancers that develop in mucosa or skin, irrespective of
histological type.
In this study, we found FHOD1 protein expression to be moderate/
high in a vast majority of malignant melanoma, as compared to benign
melanocytic tumors, i.e. nevi. This proﬁle is diﬀerent from what we
found when studying the expression of FMNL2 in clinical melanoma.
Fig. 4. FHOD1 silenced cells are more spread and contain smaller focal adhesions than control cells. A) Representative images of cells from diﬀerent cell lines 60 min
after plating. B) Percentage of spread cells for the diﬀerent cell lines. C) Area per cell calculated for the diﬀerent cell lines after 60 min of attachment time. Bars: 20 µm. * P≤0.05,
ANOVA, Tukey. D) Focal adhesions were visualized with Anti-Paxillin antibody and images were taken with an Olympus BX60 ﬂuorescence microscope. Quantiﬁcation was done from
binary images using the analyze particle tool in ImageJ. Scale bars: 20 µm. E) The number of focal adhesions per cell was quantiﬁed (50 cells per cell line). F) Quantiﬁcation of the
average area of focal adhesions per cell. Particles larger than 0.2 µm2 were counted as focal adhesions. *** P≤0.001, ANOVA, Tukey.
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In that study, we found FMNL2 to be expressed in early melanomas, at
levels that varied with similar frequency from lower to clearly higher
than detected in surrounding benign squamous cells. In that study, we
were encouraged to look for a prognostic role of FMNL2 expression,
and indeed found that the FMNL2 expression level was a negative
prognostic factor, when measured as recurrence-free survival or
melanoma-speciﬁc survival [16]. The wide expression of FHOD1 in
melanoma (and melanoma cell lines) suggested a role for FHOD1 in
tumorigenesis, rather than prognosis. Therefore, we decided to explore
the biological role of FHOD1 in melanoma. In our studies, we have
found that silencing FMNL2 or FHOD1 does not inﬂuence the
expression of the other (not shown).
We found that FHOD1 depletion was accompanied by clear
morphological and functional alterations in cultured melanoma cells.
Morphologically the cells were more rounded, had a greater area and
less prominent actin ﬁlaments with the most eﬃcient knockdown. In
functional experiments, we found that the FHOD1 depletion brought a
signiﬁcant reduction of melanoma migration in wound healing, inva-
Fig. 5. FHOD1 regulates colony formation capacity and cell proliferation. A) Representative images of colonies grown for 14 d in soft agar. B) Percentage of colonies with a
diameter exceeding 100 µm. Results are expressed as mean ± SE of 3 independent experiments (150 colonies per cell line in each experiment); C) Results from IncuCyte proliferation
assay. FHOD1 knockdown cells proliferate signiﬁcantly less than FHOD1 100% cell line. D) Histogram showing the percentages of cells in phases G0+G1 and S+G2 of the cell cycle. Cell
cycle analysis by ﬂow cytometry in WM164 FHOD1 knockdown cell lines shows that cell cycle arrest occurs in the G0+G1 phase.* P≤0.05 and ** P≤0.01, ANOVA, Tukey.
M. Peippo et al. Experimental Cell Research 350 (2017) 267–278
275
sion and even further reduction in Boyden chamber migration. These
ﬁndings are in line with alterations seen in breast cancer and oral SCC
lines earlier [7,17], suggesting that the maintenance of an elongated
and actin ﬁber rich and migratory phenotype is a common function of
FHOD1 regardless of cancer cell type. The reduction of migration in
Boyden chambers was eye-catching. Experimental setups in wound
healing and Boyden chambers are quite diﬀerent, the ﬁrst tests a more
collective mode of migration and the second challenges cells to migrate
individually through pores in a membrane. In the latter, adhesion and
detachment of individual cells have essential roles. Studies from other
groups have found FHOD1 involvement in adhesion: exogenously
expressed FHOD1 accumulates into integrin clusters, which later
mature to focal adhesions [22]. FHOD1 knockdown has been shown
to impair cell spreading and focal adhesion formation in ﬁbroblasts and
osteosarcoma cells [22,23]. In line with this, we found that FHOD1
depleted melanoma cells contain clearly smaller focal adhesions than
control cells. Focal adhesion size has been shown to predict cell
migration. Increase in focal adhesion size enhances cell speed [24].
The smaller size of focal adhesions may contribute to reduction of
melanoma cell migration, as well as more spread morphology after
FHOD1 depletion, reﬂecting reduced mechanical tension with fewer
actin ﬁlaments.
Fig. 6. FHOD1 knockdown decreases tumor growth. A) Melanoma cells from diﬀerent FHOD1 groups were in inoculated subcutaneously in both ﬂanks of nude mice.
Fluorescence images were acquired using IVIS Spectrum instrument using 570 nm excitation and 620 nm emission ﬁlters, to follow the growth of individual tumors. Overlay of light and
ﬂuorescent images 14 days after injections. The cell lines had diﬀerent levels of RFP expression and images were taken with diﬀerent exposure times (intergroup comparisons by
ﬂuorescence levels were therefore not possible). B) Curves of tumor growth and time of tumor removal. The tumors were followed up by caliper measurement. When the tumors reached
a predetermined tumor volume, the mice were euthanized and tumors were removed. FHOD1 depleted cells formed tumors reaching predetermined size slower than FHOD1 100% cells
(FHOD1 100%, 14 days; FHOD1 20%, 30 days, FHOD1 < 5%, 22 days). Mean ± SE of 5–6 tumors per group. C) Statistics of the tumor growth in each group and estimated tumor volume
at day 14. D) H&E and immunohistochemistry of tumors. In the knockdown tumors, a minor diﬀuse FHOD1 immunoreactivity was seen in FHOD1 20% cells, and small islands of
clearly FHOD1 positive cells were scattered in both 20% and 5% groups (middle row). Ki-67 staining is reduced in FHOD1 depleted cells (bottom row). Scale bars: 100 µm. E)
Proliferation rates as determined by Ki-67 staining of diﬀerent tumor groups. ** P≤0.01, ANOVA, Tukey.
M. Peippo et al. Experimental Cell Research 350 (2017) 267–278
276
An important and novel ﬁnding was inferior proliferation and cell
cycle arrest in melanoma cells depleted of FHOD1. A possible
mechanism behind this ﬁnding relates to transcriptional eﬀects of
FHOD1. FHOD1 is capable of activating the SRE through its eﬀects on
the actin cytoskeleton [7,8]. Testing this, we found that FHOD1
knockdown diminished the nuclear translocation of MKL-1 after serum
stimulation, indicating that co-activation of the SRE was reduced.
Taken together, our results suggest that FHOD1 depletion reduces
transcription from the SRE, which sequentially causes cell cycle arrest
and reduced proliferation. The eﬀect on SRE also raises the possibility
of FHOD1 inﬂuencing the transcription of focal adhesion genes in
WM164, as another explanation for the smaller focal adhesions in
knockdown cells. The SRE may control transcription of focal adhesion
genes, as has been shown in NIH-3T3 ﬁbroblasts [10].
In this study, the reduction of FHOD1 did not abrogate tumorigen-
esis in vivo. In mice, the FHOD1 silenced cells formed smaller tumors
with reduced proliferation. The tumor margins were still histologically
inﬁltrative. This suggests that a high level of FHOD1 is not indis-
pensable for invasion of melanoma cells in vivo.
Taken together, our studies identify FHOD1 as a formin commonly
upregulated in melanoma, and by studying its eﬀects in the melanoma
cell line WM164 we propose that its roles in melanoma cell biology are
diverse, involving adhesion, migration and tumor growth. However, it
may not be essential for maintenance of invasive capacity. Although the
life expectancy in metastatic melanoma has increased with modern
treatment involving cytotoxic therapies, molecular targeted therapy
and immunotherapy, advanced melanoma is still an incurable disease
[25]. Targeting actin cytoskeleton modulating proteins could be a
potential addition to the current treatment modalities. Future investi-
gations should focus on the mechanisms of FHOD1 upregulation and
activation in melanoma, to determine whether it could be utilized as a
biomarker or drug target.
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